DexCom, Inc. (DXCM) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is...
DexCom, Inc. (DXCM) currently trades at a P/E ratio of 37.59 (historical range: 24.35–66.68, median: 42.37), placing it at the 29th percentile — below its historical average, P/S ratio of 7.26 (range: 4.70–9.47, 57th percentile — near its historical average).
Over the historical period (2024-08-30 to 2026-08-28), DexCom, Inc.'s P/E ratio has contracted by 31% over the observed period (from an average of 51.9 to 36.0).
DexCom, Inc. appears undervalued relative to its historical range, with most valuation metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 37.59 | 24.35 | 42.37 | 66.68 | 29th | below its historical average |
| P/S Ratio | 7.26 | 4.70 | 7.07 | 9.47 | 57th | near its historical average |
| FCF Yield | 0.01 | 0.00 | 0.02 | 0.04 | 31th | above its historical average |